Ramelteon is a cell penetrant, potent and selective agonist at MT1/MT2 melatonin receptor that exhibits sleep-promoting properties. It is not binding to GABA receptor complex. Ramelteon is an analog of melatonin recently approved to treat insomnia.
"Perioceutics" including antimicrobial therapy and host modulatory therapy has emerged as a vital adjunctive treatment of periodontal disease. Melatonin level was significantly reduced in patients with periodontal diseases suggesting melatonin could be applied as a potential "perioceutics" treatment of periodontal
Evaluate the efficacy of ramelteon, an MT/1MT2-receptor agonist, for the treatment of transient insomnia in healthy adults. Randomized, double-blind, placebo-controlled design using a model of transient insomnia related to sleeping in a novel environment. Fourteen sleep research centers. Healthy adults
Parkinson's disease (PD) is a common neurodegenerative disease with global health and economic impact. 1-methyl-4-phenylpyridinium (MPP+)-induced mitochondrial dysfunction and oxidative stress are reported to participate in the pathological mechanism of PD. Ramelteon is a novel oral hypnotic agent that has
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.